MARCHF1

Across TCGA pan-cancer cohorts, MARCHF1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MARCHF1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MARCHF1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MARCHF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LUAD, UCEC, and SKCM are the cancer types where MARCHF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.207	0.736	<.001	24	view →
UCEC	DFS	Median	All	0.975	0.827	.011	12	view →
SKCM	OS	Median	III,IV	1.000	0.356	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MARCHF1–LUAD (DFS)

Open the LUAD breakdown →